Serina Therapeutics, Inc.
SER NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.71
KIRA · Stoqly’s AI analyst, in plain words
- Serina Therapeutics, Inc. had $0.1M of revenue in fiscal 2025, up 132.1% on the year before. Over five years, revenue changed −18.5% a year on average.
- Its operating margin was −18,478.5%, up 11,964.4 pts: of every 100 in sales, about −18,478 is left after running the business.
- Serina Therapeutics, Inc. lost $19.2M in fiscal 2025.
- Free cash flow was −$18.0M in fiscal 2025, −13,856.9% of revenue.
Market cap
$28.0M
P/E
—
Revenue
$0.1M
Net income
−$19.2M
Free cash flow
−$18.0M
Operating margin
−18,478.5%
Serina Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+132.1%
Yes. Sales grew 132.1% last year.
Does it make a profit?
−14,755.4%
No. It lost money last year.
Does profit turn into cash?
−13,856.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Serina Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- Serina Therapeutics, Inc.
- CIK
- 0001708599
Serina Therapeutics, Inc. · SER
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.0M | $3.2M | $0.1M | $0.1M |
| Revenue growth | −60.1% | −76.4% | 9,173.5% | −98.2% | 132.1% |
| Gross margin | 86.8% | 61.8% | 3.2% | — | — |
| Operating margin | −5,509.0% | −20,514.7% | −99.2% | −30,442.9% | −18,478.5% |
| Net income | −$8.7M | −$10.5M | $5.3M | −$11.1M | −$19.2M |
| Net margin | −6,024.3% | −30,770.6% | 167.1% | −19,894.6% | −14,755.4% |
| Diluted EPS | −$0.23 | −$9.70 | $0.73 | −$1.51 | −$1.91 |
| Cash | |||||
| Cash from operations | −$7.9M | −$5.9M | −$2.5M | −$17.1M | −$18.0M |
| Capital expenditure | — | — | $0.5M | $0.0M | $0.1M |
| Free cash flow | — | — | −$3.0M | −$17.2M | −$18.0M |
| FCF margin | — | — | −94.5% | −30,641.1% | −13,856.9% |
| Share count change | 0.6% | −100.0% | 668,172.7% | 0.1% | 38.5% |
| Debt and strength | |||||
| Cash and short-term investments | $0.6M | $0.6M | $7.6M | $3.7M | $3.1M |
| Debt incl. finance leases | $13.2M | $18.1M | — | — | — |
| Shareholders' equity | −$11.8M | −$37.8M | −$32.3M | $0.6M | −$0.0M |
| Current ratio | 0.2x | 0.2x | 5.4x | 2.4x | 1.7x |
| Interest coverage | −7.2x | −2.1x | −0.6x | −32.4x | −112.8x |
| Returns and quality | |||||
| Return on capital | −797.3% | — | — | — | — |
| Return on equity | — | — | — | — | −6,351.7% |
| Return on tangible equity | — | — | — | −1,738.1% | — |
| Piotroski F-score | 2 | 2 | 4 | 0 | 2 |
| Altman Z'' | −141.0 | −148.7 | −16.8 | −35.2 | −50.6 |
Insiders bought, 12 months
$0.1M
4 insiders
Insiders sold, 12 months
$0.4M
1 insider
Of sales under plans
100%
$0.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Serina Therapeutics, Inc. · SER
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.71 a share, the company is worth $28.0M.
Source: SEC EDGAR XBRL filings (CIK 0001708599). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.